Stock PEB PACIFIC EDGE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pacific Edge Limited

Equities

PEB

NZPEBE0002S1

Biotechnology & Medical Research

End-of-day quote New Zealand S.E.
Other stock markets
 06:00:00 2024-06-17 pm EDT 		5-day change 1st Jan Change
0.094 NZD 0.00% Intraday chart for Pacific Edge Limited -2.08% -19.66%
Jun. 10 New Zealand shares drop for third consecutive session, Australia closed RE
May. 21 Pacific Edge FY2024 Operating Revenue Jumps 22% to NZ$23.9 Million, Total Revenue Rises 12% to NZ$29.3 Million MT

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 75.86 735.1 777.7 348.5 68.96 76.26 - -
Enterprise Value (EV) 1 61.08 714.8 672.3 271.9 68.96 54.94 56.93 75.34
P/E ratio -3.44 x -50.5 x -36.9 x -13 x -2.36 x -2.91 x -4.55 x -7.75 x
Yield - - - - - - - -
Capitalization / Revenue 17,359,667 x 72,871,735 x 59,202,477 x 14,914,910 x 2,354,080 x - - -
EV / Revenue 13,976,600 x 70,864,101 x 51,177,812 x 11,637,548 x 2,354,080 x - - -
EV / EBITDA -3.24 x -50.1 x -33.4 x -9.85 x -2.27 x -2.06 x -2.51 x -5.29 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 5.23 x 29.7 x 7.18 x 4.21 x - 2.73 x 4.24 x 9.38 x
Nbr of stocks (in thousands) 689,652 727,779 810,087 810,365 811,271 811,271 - -
Reference price 2 0.1100 1.010 0.9600 0.4300 0.0850 0.0940 0.0940 0.0940
Announcement Date 5/29/20 5/27/21 5/25/22 5/24/23 5/20/24 - - -
1NZD in Million2NZD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 4.37 10.09 13.14 23.36 29.29 - - -
EBITDA 1 -18.83 -14.28 -20.11 -27.59 -30.36 -26.73 -22.67 -14.25
EBIT 1 -19.13 -14.58 -20.53 -29.73 -32.97 -28.46 -24.35 -15.9
Operating Margin -437.76% -144.49% -156.29% -127.24% -112.55% - - -
Earnings before Tax (EBT) 1 -18.89 -14.22 -19.79 -26.96 -29.54 -28.7 -27.87 -24.02
Net income 1 -18.89 -14.22 -19.79 -26.96 -29.54 -26.23 -22.94 -15.15
Net margin -432.17% -141% -150.64% -115.42% -100.83% - - -
EPS 2 -0.0320 -0.0200 -0.0260 -0.0330 -0.0360 -0.0323 -0.0207 -0.0121
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 5/29/20 5/27/21 5/25/22 5/24/23 5/20/24 - - -
1NZD in Million2NZD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1
Net sales 1 - 7.011 12.49 10.87 14.69
EBITDA - - - - -
EBIT 1 - -10.94 -11.67 -18.06 -17.14
Operating Margin - -156.04% -93.4% -166.12% -116.72%
Earnings before Tax (EBT) - - - -16.39 -
Net income -8.985 - - -16.39 -
Net margin - - - -150.83% -
EPS -0.0120 - - - -
Dividend per Share - - - - -
Announcement Date 11/25/21 5/25/22 11/23/22 5/24/23 11/22/23
1NZD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 - - - - - - - -
Net Cash position 1 14.8 20.3 105 76.6 - 21.3 19.3 0.92
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - -71.8% -29.6% -28.2% - -74.1% -110% -86.2%
ROA (Net income/ Total Assets) -107% -57.7% -28% -26.2% - -307% -291% -213%
Assets 1 17.72 24.65 70.59 103.1 - 8.547 7.875 7.106
Book Value Per Share 2 0.0200 0.0300 0.1300 0.1000 - 0.0300 0.0200 0.0100
Cash Flow per Share 2 -0.0300 -0.0200 -0.0200 -0.0300 - -0.0300 -0.0200 -0.0100
Capex 1 0.18 0.38 1.13 2.91 - 0.8 0.81 0.9
Capex / Sales 4.19% 3.75% 8.57% 12.45% - - - -
Announcement Date 5/29/20 5/27/21 5/25/22 5/24/23 5/20/24 - - -
1NZD in Million2NZD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.094 NZD
Average target price
0.13 NZD
Spread / Average Target
+38.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PACIFIC EDGE LIMITED Stock Pacific Edge Limited
-19.66% 46.67M
MODERNA, INC. Stock Moderna, Inc.
+34.01% 52.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.02% 38.87B
LONZA GROUP AG Stock Lonza Group AG
+34.86% 38.24B
CELLTRION, INC. Stock Celltrion, Inc.
-11.12% 26.79B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.56% 26.16B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.62% 19.9B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+39.18% 13.18B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.47% 12.24B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.40% 11.79B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PEB Stock
  4. Financials Pacific Edge Limited